IP Library Granted Patent US 7,357,941
Granted Patent B2
US 7,357,941 · App. 11/093,429 · Granted Apr 15, 2008

Method of delivering a bioactive agent with porous β-tricalcium phosphate granules

Assignee: Stryker Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,357,941
App. No.
11/093,429
Granted
Apr 15, 2008
Kind
B2
Abstract

A porous β-tricalcium phosphate material for bone implantation is provided. The multiple pores in the porous TCP body are separate discrete voids and are not interconnected. The pore size diameter is in the range of 20-500 μm, preferably 50-125 μm. The porous β-TCP material provides a carrier matrix for bioactive agents and can form a moldable putty composition upon the addition of a binder. Preferably, the bioactive agent is encapsulated in a biodegradable agent. The invention provides a kit and an implant device comprising the porous β-TCP, and a bioactive agent and a binder. The invention also provides an implantable prosthetic device comprising a prosthetic implant having a surface region, a porous β-TCP material disposed on the surface region and optionally comprising at least a bioactive agent or a binder. Methods of producing the porous β-TCP material and inducing bone formation are also provided.

Claims (11)

1. A method of delivering a bioactive agent at a site in a mammal requiring bone formation, comprising implanting at the site a composition comprising

porous β-tricalcium phosphate (β-TCP) granules that have a particle size of 0.1-2 mm and that comprise a multiplicity of pores having a pore diameter size of 20-500 μm and being single separate voids partitioned by walls and being not interconnected and

a bioactive agent.

2. The method of claim 1 , wherein the bioactive agent is a bone morphogenic protein.

3. The method of claim 1 , wherein the bioactive agent is encapsulated in a biodegradable agent.

4. The method of claim 3 , wherein the delivery of the bioactive agent is sustained released.

5. The method of claim 1 , wherein the bioactive agent is a nucleic acid molecule comprising a sequence encoding a bone morphogenic protein.

6. The method of claim 3 , wherein the biodegradable agent is poly(lactide-co-glycolide) (PLGA).

7. The method of claim 1 , wherein the composition further comprises carboxy methylcellulose sodium.

8. The method of claim 1 , wherein the porous β-TCP granules have a particle size of 0.5-1 mm.

9. The method of claim 1 , wherein the pore diameter size is 50-125 μm.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2014
From: DALAL, PARESH S.; DIMAANO, GODOFREDO R.; TOTH, CAROL ANN; KULKARNI, SHAILESH C.
To: STRYKER CORPORATION
Reel/Frame 033995/0695 →
MERGER Recorded Oct 21, 2014
From: STRYKER DEVELOPMENT LLC
To: HOWMEDICA OSTEONICS CORP.
Reel/Frame 033995/0713 →
Continuity (3)
Division 0996078900 · Sep 21, 2001
Continuation In Part 0979851800 · Mar 2, 2001
Related Publication 20060292198A1 · Dec 28, 2006